Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more
Market Cap & Net Worth: Lavipharm S.A (LAVI)
Lavipharm S.A (AT:LAVI) has a market capitalization of $212.73 Million (€207.25 Million) as of March 18, 2026. Listed on the AT stock exchange, this Greece-based company holds position #19144 globally and #31 in its home market, demonstrating a 3.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lavipharm S.A's stock price €1.23 by its total outstanding shares 169043561 (169.04 Million).
Lavipharm S.A Market Cap History: 2015 to 2026
Lavipharm S.A's market capitalization history from 2015 to 2026. Data shows growth from $67.83 Million to $212.73 Million (8.44% CAGR).
Lavipharm S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lavipharm S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.61x
Lavipharm S.A's market cap is 2.61 times its annual revenue
0.00x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
15.36x
Lavipharm S.A's market cap is 15.36 times its annual earnings
0.03x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $67.83 Million | $26.37 Million | -$7.07 Million | 2.57x | N/A |
| 2016 | $41.68 Million | $31.14 Million | $3.66 Million | 1.34x | 11.39x |
| 2017 | $79.47 Million | $31.81 Million | $12.93 Million | 2.50x | 6.15x |
| 2018 | $67.83 Million | $34.06 Million | $1.25 Million | 1.99x | 54.31x |
| 2019 | $106.59 Million | $33.59 Million | $5.33 Million | 3.17x | 20.01x |
| 2020 | $227.74 Million | $37.64 Million | $2.17 Million | 6.05x | 105.19x |
| 2021 | $281.03 Million | $39.72 Million | $1.72 Million | 7.07x | 163.11x |
| 2022 | $66.63 Million | $46.01 Million | $834.00K | 1.45x | 79.89x |
| 2023 | $138.12 Million | $47.84 Million | $1.87 Million | 2.89x | 73.82x |
| 2024 | $137.95 Million | $52.95 Million | $8.98 Million | 2.61x | 15.36x |
Competitor Companies of LAVI by Market Capitalization
Companies near Lavipharm S.A in the global market cap rankings as of March 18, 2026.
Key companies related to Lavipharm S.A by market ranking:
- Tsumura & Co (MU:TSUA): Ranked #5658 globally with a market cap of $1.58 Billion USD ( €1.54 Billion EUR).
- Medicon Hellas S.A. (AT:MEDIC): Ranked #43543 globally with a market cap of $23.83K USD ( €23.21K EUR).
- AN2 Therapeutics Inc (NASDAQ:ANTX): Ranked #19135 globally with a market cap of $80.73 Million USD.
- RideNow Group, Inc. (NASDAQ:RDNW): Ranked #19145 globally with a market cap of $80.55 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5658 | Tsumura & Co | MU:TSUA | $1.58 Billion | €23.60 |
| #43543 | Medicon Hellas S.A. | AT:MEDIC | $23.83K | €2.44 |
| #19135 | AN2 Therapeutics Inc | NASDAQ:ANTX | $80.73 Million | $5.00 |
| #19145 | RideNow Group, Inc. | NASDAQ:RDNW | $80.55 Million | $5.95 |
Lavipharm S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Lavipharm S.A's market cap moved from $67.83 Million to $ 212.73 Million, with a yearly change of 8.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €212.73 Million | +26.39% |
| 2025 | €168.31 Million | +22.01% |
| 2024 | €137.95 Million | -0.13% |
| 2023 | €138.12 Million | +107.29% |
| 2022 | €66.63 Million | -76.29% |
| 2021 | €281.03 Million | +23.40% |
| 2020 | €227.74 Million | +113.66% |
| 2019 | €106.59 Million | +57.15% |
| 2018 | €67.83 Million | -14.65% |
| 2017 | €79.47 Million | +90.67% |
| 2016 | €41.68 Million | -38.55% |
| 2015 | €67.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Lavipharm S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $212.73 Million USD |
| MoneyControl | $212.73 Million USD |
| MarketWatch | $212.73 Million USD |
| marketcap.company | $212.73 Million USD |
| Reuters | $212.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.